We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets... Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. Show more
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science...
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter...
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease expected in the first half of 2024 Initiation of a Phase 1 study to...
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a...
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel...
CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD - Poster presentation showcases method used to...
- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.25 | -7.28862973761 | 3.43 | 3.49 | 3.1 | 369189 | 3.15219823 | CS |
4 | -0.94 | -22.8155339806 | 4.12 | 4.275 | 3.1 | 251257 | 3.56008556 | CS |
12 | -0.04 | -1.24223602484 | 3.22 | 5.09 | 2.8949 | 343542 | 3.79918706 | CS |
26 | -0.23 | -6.74486803519 | 3.41 | 5.09 | 1.8101 | 453158 | 3.18514602 | CS |
52 | -0.55 | -14.745308311 | 3.73 | 11.3099 | 1.8101 | 581064 | 5.70470179 | CS |
156 | -21.89 | -87.3155165536 | 25.07 | 26.98 | 1.8101 | 421103 | 7.32990748 | CS |
260 | -21.89 | -87.3155165536 | 25.07 | 26.98 | 1.8101 | 421103 | 7.32990748 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions